Business
Ligand to Hold Investor and Analyst Day on December 13
SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St.
About this update from Ligand Pharmaceuticals Incorporated
[{"type":"text","content":" SAN DIEGO--(BUSINESS WIRE)--\nLigand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that it will hold an Investor and Analyst Day at The St. Regis New York on December 13, 2022, from 11:00 a.m. to 12:30 p.m. Eastern time (8:00 a.m. to 9:30 a.m. Pacific time). A live and archived webcast will be available for those unable to attend in person. Presenters will include:\n\n\nJohn Higgins, Chief Executive Officer\n\n\nMatt Korenberg, President and Chief Operating Officer\n\n\nTavo Espinoza, Chief Financial Officer\n\n\nAndrew Reardon, Chief Legal Officer\n\n\nDiane Retallack, Senior Vice President of Platform Technology and Innovation\n\n\nPresentations by Ligand executives will address the following topics:\n\n\nCommentary on Ligand’s business model, financial outlook and capital deployment strategy\n\n\nOverview of Ligand’s technology platforms\n\n\nOverview of core partner and license assets\n\n\nReview of Ligand’s intellectual property and patent portfolio\n\n\nDiscussion of Ligand’s commitment to ESG and ongoing corporate sustainability initiatives\n\n\nThe presentations will be followed by lunch for those attending in person. The live and archived webcast can be accessed here. For more information or make a reservation to attend, please contact Carolyn Curran at [email protected].\n\nAbout Ligand Pharmaceuticals\n\nLigand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) ultimately to generate our revenue. Ligand’s Captisol® platform technology is a patent-protected, chemically modified cyclodextrin with a structure designed to optimize the solubility an...